FilingReader Intelligence

Lukang Pharma plans private placement of A shares in 2024

June 18, 2025 at 05:00 AM UTC•By FilingReader AI

Shandong Lukang Pharmaceutical (SSE:600789) is moving forward with plans for a private placement of A shares aimed at specific investors, as indicated by the China International Capital Corporation Limited's (CICC) letter of sponsorship. The initiative is still subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission (CSRC).

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

China International Capital Corporation Limited's letter of sponsorship for the issuance of A shares to specific objects by Shandong Lukang Pharmaceutical Co., Ltd. in 2024June 17, 2025 at 08:00 AM UTC

Supplementary Source Documents

Hexin Certified Public Accountants (Special General Partnership)'s response to the inquiry letter on the review of Shandong Lukang Pharmaceutical Co., Ltd.'s application documents for issuing shares to specific objectsJune 17, 2025 at 08:00 AM UTC

Shandong Lukang Pharmaceutical

SSE:600789•Shanghai Stock Exchange

Animal Health

RSS feed for Shandong Lukang Pharmaceutical

News Alerts

Get instant email alerts when Shandong Lukang Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →